Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results, Misses Expectations By $0.52 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.52), Zacks reports.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP traded up $0.14 during trading on Wednesday, reaching $4.39. 48,054 shares of the stock were exchanged, compared to its average volume of 229,579. Oramed Pharmaceuticals has a 12-month low of $1.98 and a 12-month high of $5.19. The firm’s 50-day moving average price is $4.14 and its 200 day moving average price is $3.82. The firm has a market cap of $182.44 million, a price-to-earnings ratio of 1.07 and a beta of 1.22.

Insider Buying and Selling at Oramed Pharmaceuticals

In other news, CFO Avraham Gabay sold 73,360 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total value of $330,853.60. Following the completion of the sale, the chief financial officer owned 671,785 shares of the company’s stock, valued at $3,029,750.35. This represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joshua Hexter sold 137,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total value of $611,020.00. Following the transaction, the chief operating officer owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. This represents a 11.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently modified their holdings of ORMP. Marshall Wace LLP acquired a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at approximately $738,000. HRT Financial LP acquired a new stake in Oramed Pharmaceuticals during the fourth quarter worth about $131,000. Quadrature Capital Ltd bought a new position in Oramed Pharmaceuticals in the fourth quarter worth about $119,000. Squarepoint Ops LLC boosted its stake in Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 28,406 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Oramed Pharmaceuticals by 31.2% during the 4th quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 18,600 shares during the period. Institutional investors and hedge funds own 12.73% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.